| About more than twenty percent of patients with acute myeloid leukemia(AML) can’t achieve a complete remission(CR) after induction therapy or relapse quickly after CR. The patients with relapsed or refractory acute myeloid leukemia usually have a poor prognosis, because of the limited treatments. How to improve the treatment outcome of patients with relapsed or refractory acute myeloid leukemia effectively is still a challenge for clinic practice. This review summarized the present situation in the treatment which includes combined chemotherapy, drug resistance reversal,hematopoietic stem cell transplantation, immunomodulatory agents and traditional Chinese medicine. We also focus on findings of new anti-leukemia drugs, some in these fields like molecular targeted drugs will also be detailed in this review. |
PDF Full Text Request